Rallis Chris A's Form 4 filing
Fennec Pharmaceuticals Inc. (FENC) · filed Oct 10, 2024
- Accession no.
- 0001415889-24-024986
- Filed
- Oct 10, 2024
- Trade date
- Oct 8, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $6.37K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Rallis Chris ACIK 0001185945 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2024 | Common Shares | MOption exerciseAcquired | +1,960 | $2.55 | +$4,998 | 50,029 | Direct | |
| Oct 8, 2024 | Common Shares | SSaleDisposed | −1,406 | $4.53 | −$6,369.18 | 48,623 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2024 | Options | MOption exerciseDisposed | −1,960 | $2.55 | −$4,998 | 194,698 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.